Certain diisoniazid methane sulfonate complexes

ABSTRACT

CONSTITUTING AN IMPROVED TUBERCULOSTATIC AGENT AND METHOD OF PREPARING THE SAME BY REACTING D(+)2,2&#39;&#39;(ETHYLENEDIIMINO) DI-1BUTANOL AND ISONIAZID METHANE SULFONIC ACID.   Di-isoniazidmethane sulfonate of d(+)2,2&#39;&#39;(ethylenediimino)di-1butanol having the formula

United States Patent [191 Ferrer-Salat et al.

CERTAIN IHISONIAZID METHANE SULFONATE COMPLEXES inventors: Carlos Ferrer-Salat, Jorge- Ferrar- Batlles, Juan Colome-Riera, all 'of Barcelona, Spain Assignee: Laboratores Ferrer S.L., Barcelona, Spain- Filed: July 28, 1910 Appl. No.: 59,010

Foreign Application Priority Data -J uly 28, 1969 Spain ..369,952

u.s. Cl. .;....'.....260/294.8 n, 260/2941; 11, 260l294.8 s, 424/266 rm. Cl. ..C07d 31/48 Field of Search.260/294.8 R, 294.8 H, 294.8 SB

References Cited UNITED STATES PATENTS 2/1960 Gardner et al. ..260/294.8 2/1966 Distler et al. ..260/294.8

[ 51 Feb. 27, 1973 OTHER PUBLICATIONS Burger, Medicinal Chemistry, Third Edition, Part I,

' Wiley lntersc'ience, pages 436-437 (1970).

Fiese'r & Fieser, Advanced Organic Chemistry, Reinhold Publishers, Pages 698-699, (1961).

Primary Examiner-Alan L. Rotman Attorney-Michael S. Striker [5 7] ABSTRACT Di-isoniazidmethane sulfonate of d(+)2,2'( ethylenediimino)di-1-butanol having the formula I on on C ONIINH-Clir-SOgll 2 Claims, No Drawings CERTAIN DIISONIAZID METHANE SULFONATE COMPLEXES The present invention refers to a new process for obtaining isoniazid derivatives, having tuberculostatic action, which avoid nervous types of toxic side-effects of petroleum ether, and crystallization occurs on freezing at 4C. The product is then filtered on a Buchner filter,

and washed several times with a mixture of methanol the same, and also the sudden appearance of resistant I strains and, show superior bacteriostatic action to that of isoniazid.

The process for obtaining these derivativesis based tn ams l 9 1h? sxm st s read es betw en d(+)2,2(ethylenediimino)di-1-butanol and isoniazid EXAMPLE (A) One hundred thirty-eight g of isoniazid are treated with cc of formaldehyde (-40 percent) in aqueous solution to obtain a formaldehyde derivative having an empirical formula C,H N O. The formaldehyde derivative, previously suspended in water, is thoroughly stirred, and a stream of 80 from a'pressure bottle passed through it. isoniazid methane sulphonic acid is thus obtained.

Four hundred sixty-two g of isoniazid methane sulphonic acid is suspended in 1800 ml of ethanol together wmffl tgoffifi,Tlethyleiiediirnififidi l butanol; the mixture is heated on a water bath until completely dissolved. A yellow solution is obtained which when treated for a few minutes with active charcoal becomes practically-colorless after filtration. After cooling, the resulting solution is treated with petroleum ether until turbulency persists, and crystallization occurs on freezing; the product is washed with ethanol ether and dried under vacuum over P 0 The product is purified by dissolving in hot ethanol, small impurities are filtered off, and the product crystallized by addition of petroleum ether.

EXAMPLE (B) Twenty-eight g. of d(-F)2,2'(ethylenediimino)di-1-- butanol dihydrochloride and 58 g of sodium isoniazid methane sulphonate dihydrate are then, allowed to react in methanol under reflux for between 1 and 2 hours.

The NaCl formed is filtered. The solvent is then removed by evaporation until half the original volume is obtained. The resulting solution is treated with and petroleum ether.

The product is purified by dissolving hot followed by freezing to give total crystallization.

EXAMPLE (C) 20.4 g of d(+)2,2(ethylenediimino)di l butanol dihydrochloride are dissolved in absolute ethyl alcohol with 12.8 g of NaHCO NaCl precipitates and is separated by filtration. Forty-six g of isoniazid methane sulphonic acid are then added to the solution. A part of the solvent is eliminated by evaporation until half of the original volume remains. The resulting solution is treated with petroleum ether, and crystallizes on freezing at 4C. The product is then filtered on a Buchner filter and washed several times with a mixture of methanol and petroleum ether.

The product is purified by dissolving hot followed by freezing to give total crystallization.

. The product obtained is di-isoniazid methane sulphiriate of YTGE ,2 (etl'ifl eriediimino fii l-butanol; it has a molecular weight of 666.81, an empirical formula of C H 2NgO S and a structural formula:

p It is a white powder which crystallizes in the form of needles, the melting point is l21-122C with decomposition. It is soluble in water, methanol, N,N- dimethylformamide, acids and bases; it is insoluble in ethanol, ethyl ether and chloroform.

The U.V. spectrum shows an absorption maximum at 265 my. and a minimum at 237 mg.

The specific rotation in a 5 percent aqueous solution is: [a] 3 Chromatography:

Support: chromatographic plates F Eluant: methanol Developer: U.V. lamp Test concentration: 200 mg./cc.

Isoniazid methane sulphonate of d(+)2,2(ethylenediimino)di-l-butanol gives an Rf value of 0.56- 0.65.

The acute toxicity of di-isoniazid methane sulphonate of d(+)2 ,2 (ethylenediimino)dil -butanol was determined 'in parallel experiments for the component products of the compound obtained according to the process referred to in this specification giving the following LD 50 values for oral administration in the mouse: 2.800 g/kg for this product; 0.365 g/kg for the isoniazid; 2.175 g/kg for the isoniazid methane sulphonate Nail-I 0. Values for LD 50 were also obtained for these-substances for intraperitoneal administration in the mouse, as follows: 2.210 g/kg for this p equel 9.12 lk for the 9E i Hills ks??? h d(+)2 ,2 (ethylenediimino)dil -butanol.

Experiments to determine the bacteriostatic action of the product were carried out on H37Rv bacteria cultures, and the minimum inhibitory doses obtained for the isoniazid and the d(+)2,2(ethylenediimino)dilbutanol were determined in parallel experiments. In the solid Liiwenstein medium bacteriostatic action was observed at a dose of 0.05 g/ml for the di-isoniazid methane sulphonate of d(+)2,2(ethylenediimino)di-lbutanol and the isoniazid. n the other hand the inhibitory values for d(+)2,2(ethylenediimino)di-l-butanol were of the order of 0.75 g/ml, clearly much higher than those of the other products observed. Identical results were obtained with the same H37Rv bacterial culture in Sautons liquid medium for the three substances tested in parallel experiments.

Experiments to determine the induced resistance of this product were carried out on pathogenic mycobacteria maintained on successive cultures in the presence of increasing doses of the product. The human culture H37Rv was used as the internationally best known virulence model, cultivated in three different nutritive media. Parallel experiments with isoniazid were also carried out. The results showed that, in the Lowenstein medium, both isoniazid and di-isoniazid methane sulphonate of d(+)2,2'(ethylenediimino)dil -butanol induce a habit-forming resistance which requires inhibitory doses of the same order for both (0.21 g/ml).

ln Sautons medium the inhibitory doses are of the order of 0.18 g/ml for the product of the invention and, similarly as for the isoniazid, no appreciable amount of induced resistance was observed.

In the Dubos albuminous medium with fraction V- it was observed that, for isoniazid, the necessary inhibitory doses were higher than those required to inhibit the culture. However, as far as di-isoniazid methane sulphonate of d(+)2,2'(ethylenediimino)di-lbutanol was concerned, surprisingly no induced resistance was observed; on the contrary successive steps in the presence of the compound showed a bacteriostatic action which required very small inhibitory doses on the original culture 1.20 g/ml).

The compound obtained according to the process of the invention can be administered, mixed with suitable excipients, in the form of tablets (plain or coated), capsules or injectable solutions at a dose between 500 and 3 ,000 milligrams daily.

Having thus described the fundamental details of the process and the compound obtained, referred to in the present patent, it must be noted that experience can allow several variations in detail without modification of the fundamental idea, which is stated and summarized in the following.

We claim: 1. The compound winch has the formula CH1 0 H3 2. Di-isoniazid methane sulphonate of d(+) 2, 2' (ethylenediimino) di- 1 -butanol. 

2. Di-isoniazid methane sulphonate of d(+) 2, 2'' (ethylenediimino) di-1-butanol. 